The Q2 results met the consensus expectations as strong momentum across the therapeutic areas and a healthy performance from the Diagnostics base business compensated for biosimilar erosion and falling sales of COVID-19 tests. Consequently, the 2023 guidance remained unchanged. Overall, despite the key patent expiries in recent years, Roche continues to benefit from enviable w.r.t profit margins, stakeholder returns and a market-leading position in key therapeutic areas. Moreover, a boost in the ....
